SEC Filing Analysis: Tharimmune, Inc. (THAR)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Jill E. Sommers has been appointed as a new director and, as of the event date, holds no shares in Tharimmune, Inc.
• Market Impact: Neutral. This is a standard corporate governance disclosure with no immediate market-moving information.

Company Information

Field	Value
Company	Tharimmune, Inc.
Ticker Symbol	THAR
CIK	0001861657
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Sommers Jill E.
CIK	0001737622
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	3
Transaction Date	2026-01-30
Transaction Code	null
Security Type	null
Shares Involved	0
Price Per Share	null
Total Value	null
Shares Owned After	0
Ownership Type	null

Financial Impact Assessment

Transaction Materiality

As this is a Form 3 reporting zero initial holdings, there is no financial transaction to assess.

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	0
% of Shares Outstanding	0.00%
Post-Transaction Ownership	0 shares (0.00% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Tharimmune, Inc. is a small-cap company with a market capitalization of approximately $160 million. This filing is a governance event, not a financial transaction, and has no impact on the company's valuation.
• Ownership Concentration: The new director's appointment does not alter insider ownership concentration, as she holds no shares.
• Dilution Impact: Not applicable, as no new shares were issued.
• Transaction Significance: The significance is purely informational, noting the addition of a new board member.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: A Form 3 filing for a new director who owns no stock is a routine disclosure. It does not provide any new financial signal to the market.

Volume & Sentiment

• Expected Volume Impact: None. This type of filing typically does not influence trading volume.
• Sentiment Indicator: Neutral. The filing confirms a new director appointment but offers no bullish or bearish signals.

Key Takeaways

1. New Director: Tharimmune, Inc. has appointed Jill E. Sommers to its Board of Directors.
2. No Initial Holdings: The filing explicitly states that the new director owned no company securities as of the effective date.
3. Informational Filing: This Form 3 serves as a baseline declaration of ownership and is a standard procedural filing under SEC regulations.

Additional Context

Transaction Notes

• This Form 3 is an initial statement of beneficial ownership, required upon an individual becoming a corporate insider. The tag <noSecuritiesOwned>1</noSecuritiesOwned> in the filing confirms the zero-share balance.